Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Seborrhea in Parkinson's disease may be linked to hormones, not autonomic impairment.

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.

This review discusses various weight loss treatment options for managing PCOS in women, including lifestyle changes, diet, medications, and surgery, but reports no new clinical results.

This report details the experiences gained during a pharmacy internship in both hospital and community settings, highlighting the preparation of sildenafil suspensions for hospital use, patient consultations on autoimmune conditions, and educational material creation in community pharmacy, alongside insights into diabetes and ADHD treatments.

This narrative review suggests that the association between weight-loss medications and telogen effluvium is primarily due to metabolic changes from rapid weight loss, rather than a direct pharmacological effect on hair follicles.

This summary of a pharmacy internship reports on expanding scientific knowledge through diverse activities, including exploring diabetes medications for obesity treatment and discussing the role of nutritional supplements in geriatrics.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study found that subcutaneous injections of guanethidine or 6-hydroxydopamine induced premature hair growth in mice, suggesting a role for sympathetic nerves in hair growth control.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This review discusses the molecular role of the vitamin D receptor in regulating various biological actions such as bone mineralization and reports no new clinical results, highlighting the complexity of vitamin D's function in multiple tissues.

This overview discusses primary cicatricial alopecias, focusing on lichen planopilaris, and highlights the challenges in treatment and the progressive nature of hair loss despite symptom management, without providing new clinical results.

This study found that spironolactone reduced fish fecundity and caused masculinization of females at certain concentrations, while having no effect on Daphnia magna reproduction, underscoring concerns for environmental exposure to vertebrates.

This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

Tailored medication preparation and ongoing education are crucial for effective treatments.

This minireview discusses a proposed model of the vitamin D receptor that explains how 1alpha,25(OH)2D3 can mediate both genomic and rapid responses through different ligand shapes and cellular locations, without presenting new research findings.

This review examines the impact of vitamin D signaling in extraskeletal tissues and notes that expected benefits from animal and cell studies have not been consistently replicated in human clinical trials.

This review highlights that vitamin D is increasingly recognized for its roles in skin health, including treatment of psoriasis, potential applications in conditions like atopic dermatitis, and possible prevention of skin malignancies, as observed in various studies linking low levels to autoimmune skin diseases.

In this study, a clear pattern of selective sweep was observed for the SLC24A5 gene, with high linkage disequilibrium and low haplotype diversity, but no clear correlation with UV radiation intensity was found.

This review summarizes the proposed model that describes how different shapes of 1alpha,25(OH)2D3 ligands interact with the vitamin D receptor to mediate genomic and rapid responses in cells.

In this study, mutations in the vitamin D receptor were identified in Brazilian children with rickets and alopecia, leading to impaired receptor activation and reduced 24-hydroxylase expression.

This research observed that, in domestic cats like Maine Coon and Rex breeds, a "piebald" coat color pattern is likely influenced by the Silver locus, although the specific mutations involved are yet to be published.

This study found that carbonic anhydrase II was significantly upregulated in human keratinocytes when treated with toll-like receptor 3 agonist and Th2 cytokines, suggesting its potential role in inflammatory skin conditions.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.